Source: D’Onofrio G, Hawk KF, Perrone J, et al. Incidence of Precipitated Withdrawal During a Multisite Emergency Department–Initiated Buprenorphine Clinical Trial in the Era of Fentanyl. JAMA Netw Open. 2023;6(3):e236108. doi:10.1001/jamanetworkopen.2023.6108 Discussion This cohort study used data...

Source: Day, N., Wass, M. & Smith, K. Virtual opioid agonist treatment: Alberta’s virtual opioid dependency program and outcomes. Addict Sci Clin Pract 17, 40 (2022). https://doi.org/10.1186/s13722-022-00323-4 Abstract Background Virtually delivered healthcare (telehealth, telemedicine) has the...

Source: Andraka-Christou, B., Page, C., Schoebel, V. et al. Perceptions of buprenorphine barriers and efficacy among nurse practitioners and physician assistants. Addict Sci Clin Pract 17, 43 (2022). https://doi.org/10.1186/s13722-022-00321-6 Abstract Background Medications for opioid use disorder...

Source: Hodgins, D. C., Budd, M., Czukar, G., Dubreucq, S., Jackson, L. A., Rush, B., ... & Cameron Wild, T. (2022). Treatment of Opioid Use Disorder in Canadian Psychosocial Addiction Programs: A National Survey of Policy, Attitudes, and Practice. The Canadian Journal of Psychiatry...

Source: Pasman, E., Kollin, R., Broman, M. et al. Cumulative barriers to retention in methadone treatment among adults from rural and small urban communities. Addict Sci Clin Pract 17, 35 (2022). https://doi.org/10.1186/s13722-022-00316-3 Abstract Background Though methadone has been shown to...

Source: Meyers-Pantele, S.A., Mittal, M.L., Jain, S. et al. The influence of poly-drug use patterns on the association between opioid agonist treatment engagement and injecting initiation assistance. Subst Abuse Treat Prev Policy 17, 39 (2022). https://doi.org/10.1186/s13011-022-00470-6 Abstract...

Source: Ford, B. R., Bart, G., Grahan, B., Shearer, R. D., & Winkelman, T. N. (2020). Associations Between Polysubstance Use Patterns and Receipt of Medications for Opioid Use Disorder Among Adults in Treatment for Opioid Use Disorder. Journal of Addiction Medicine. Abstract Objective: To examine...

Source: Langabeer, J., Stotts, A. L., Cortez, A., Tortolero, G., & Champagne-Langabeer, T. (2020). Geographic proximity to buprenorphine treatment providers in the US. Drug and alcohol dependence, 108131. Highlights •Access to treatment remains a concern for patients with opioid use disorder....

Source: Meges D, Zevin B, Cookson E, Bascelli L, Denning P, Little J, Doe-Simkins M, Wheeler E, Watlov Phillips S, Bhalla P, Nance M, Cobb G, Tankanow J, Williamson J, Post P (Ed.). Adapting Your Practice: Recommendations for the Care of Homeless Patients with Opioid Use Disorders. 102 pages...

Source: Nelson LF, Yocum VK, Patel KD, Qeadan F, Hsi A, Weitzen S. Cognitive Outcomes of Young Children After Prenatal Exposure to Medications for Opioid Use Disorder: A Systematic Review and Meta-analysis. JAMA Netw Open. 2020;3(3):e201195. doi:10.1001/jamanetworkopen.2020.1195 Key Points Question...

Source: Katzman JG, Takeda MY, Greenberg N, et al. Association of Take-Home Naloxone and Opioid Overdose Reversals Performed by Patients in an Opioid Treatment Program. JAMA Netw Open. 2020;3(2):e200117. doi:10.1001/jamanetworkopen.2020.0117 Key Points Question Is there a benefit associated with...

Source: https://store.samhsa.gov/system/files/pep19-mat-corrections.pdf Medication-assisted treatment (MAT) is the use of FDA-approved medications in combination with behavioral therapies to treat alcohol and opioid use disorders. When provided as part of the rehabilitation and reentry process for...

Source: Scheibe, A., Shelly, S., Gerardy, T. et al. Six-month retention and changes in quality of life and substance use from a low-threshold methadone maintenance therapy programme in Durban, South Africa. Addict Sci Clin Pract 15, 13 (2020). https://doi.org/10.1186/s13722-020-00186-7 Abstract...

Source: Nguyen JL, Gilbert LR, Beasley L, et al. Availability of Naloxone at Rural Georgia Pharmacies, 2019. JAMA Netw Open. 2020;3(2):e1921227. doi:10.1001/jamanetworkopen.2019.21227 Discussion Although the legislative barrier to obtaining naloxone has been addressed in Georgia, naloxone...

Source: Wakeman SE, Larochelle MR, Ameli O, et al. Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder. JAMA Netw Open. 2020;3(2):e1920622. doi:10.1001/jamanetworkopen.2019.20622 Key Points Question What is the real-world effectiveness of different treatment pathways...

Source: https://www.thenationalcouncil.org/medication-assisted-treatment-for-opioid-use-disorder-in-jails-and-prisons/?mkt_tok=eyJpIjoiTVRZM09UbGlaVGt3T0RRMiIsInQiOiJOeldcL0wyWGZSbFMxcFhQUkNoY2FkUU9yZkErMDNGelNUY2o4d0NCalJcL1BQTE1QTklDTnAwZlB2VVVrY0wrWVlDTk9na2FzMzhSZnFneXVcL0drblAxdz09In0%3D People...

Source: Huhn AS, Hobelmann JG, Strickland JC, et al. Differences in Availability and Use of Medications for Opioid Use Disorder in Residential Treatment Settings in the United States. JAMA Netw Open. 2020;3(2):e1920843. doi:10.1001/jamanetworkopen.2019.20843 Key Points Question Do residential...

Source: Ahamad, K., Dong, H., Johnson, C. et al. Factors associated with willingness to wear an electronic overdose detection device. Addict Sci Clin Pract 14, 23 (2019). https://doi.org/10.1186/s13722-019-0153-5 Abstract Background North America is in the midst of an opioid overdose epidemic...

Source: Warrington et al. Addict Sci Clin Pract (2020) 15:3 https://doi.org/10.1186/s13722-020-0178-9 Abstract Background Urine drug monitoring for medications for opioid use disorder (MOUD) such as buprenorphine can help to support treatment adherence. The practice of introducing unconsumed...

Source: Pytell, J.D., Buresh, M.E. & Graddy, R. Outcomes of a novel office-based opioid treatment program in an internal medicine resident continuity practice. Addict Sci Clin Pract 14, 46 (2019) doi:10.1186/s13722-019-0175-z Abstract Background The integration of opioid use disorder (OUD) care and...